FindTrial
Sign In

The patients reported outcomes of HR-positive HER2-negative advanced breast cancer treated with different CDK4/6 inhibitors

The patients reported outcomes of HR-positive HER2-negative advanced breast cancer treated with different CDK4/6 inhibitors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081747
Enrollment
Unknown
Registered
2024-03-11
Start date
2024-03-30
Completion date
Unknown
Last updated
2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Experimental group:Abemaciclib
Control group:Paiboxili
Control group:Dalpiciclib
Control group:Ribociclib

Sponsors

The First Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Age =18 years old, gender is not limited; ? Relevant tests have been identified as HR+/HER2- advanced breast cancer patients ? For the first time, the above four CDK4/6 inhibitors combined with endocrine therapy ? Patients without surgical treatment before medication

Exclusion criteria

Exclusion criteria: ? Patients with HR- or TNBC were confirmed by postoperative pathology; ? History of CDK4/6 inhibitor treatment; ? Combined with multiple tumors, multiple organ failure, ? Surgical treatment has been performed.

Design outcomes

Primary

MeasureTime frame
Total score of Chinese Advanced Breast Cancer PROs Scale (NCC-BC-A);—

Secondary

MeasureTime frame
General statistics;—

Countries

China

Contacts

Public ContactXiaowei Qi

The First Affiliated Hospital of Army Medical University

qxw9908@foxmail.com+86 135 2754 5423

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026